April 29, 2020 / 3:20 PM / a month ago

BRIEF-The Lancet Says As China Study Was Stopped Early, True Effectiveness Of Remdesivir Remains Unclear

April 29 (Reuters) - THE LANCET:

* THE LANCET - RANDOMISED TRIAL OF REMDESIVIR IN CHINA SUGGESTS ANTIVIRAL DRUG IS NOT ASSOCIATED WITH SIGNIFICANT CLINICAL BENEFITS, MORE RESEARCH NEEDED

* THE LANCET - TRUE EFFECTIVENESS OF REMDESIVIR REMAINS UNCLEAR AS CHINA STUDY WAS STOPPED EARLY BECAUSE OF DIFFICULTY RECRUITING PATIENTS

* THE LANCET - TREATMENT WITH REMDESIVIR DID NOT SPEED RECOVERY OR REDUCE DEATHS FROM COVID-19 VERSUS PLACEBO IN HOSPITALISED PATIENTS IN CHINA TRIAL

* THE LANCET - NO STATISTICALLY SIGNIFICANT DIFFERENCE IN TIME TO CLINICAL IMPROVEMENT WAS NOTED BETWEEN REMDESIVIR GROUP VERSUS PLACEBO GROUP IN CHINA TRIAL

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below